ReviewTuberculosis and respiratory diseases2014
Clinical Aspect of MicroRNA in Lung Cancer.
Review in Tuberculosis and respiratory diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- [Role and Significance of Bioactive Substances in Sputum in the Diagnosis of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021Review
- miR-15b enhances the proliferation and migration of lung adenocarcinoma by targeting BCL2.Thoracic cancer · 2020Article
- MicroRNAs in Vascular Eye Diseases.International journal of molecular sciences · 2020Review
- MiR-199a-5p suppresses non-small cell lung cancer via targeting MAP3K11.Journal of Cancer · 2019Article
- Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis.BioMed research international · 2017Article
- Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease.Oncotarget · 2016Article
- Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer.Oncotarget · 2016Article
- miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer.OncoTargets and therapy · 2015Article
- Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms.Journal of hematology & oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are a class of small noncoding RNAs that modulate target gene activity, and are aberrantly expressed in most types of cancer as well in lung cancer. A miRNA can potentially target a diverse set of mRNAs; further, it plays a critical role in lung tumorigenesis as well as affects patient outcome. Previous studies focused mainly on abnormal miRNAs expressions in lung cancer tissues. Interestingly, circulating miRNAs were identified in human plasma and serum in 2008. Since then, considerable effort has been directed to the study of circulating miRNAs as one of the biomarkers of lung cancer. miRNAs expression of tissues and blood in lung cancer patients is being analyzed by more researchers. Recently, to overcome the high false-positivity of low-dose chest computed tomography scan, miRNAs in lung cancer screening are being investigated. This article summarizes the recent researches regarding clinical applications of miRNAs in the diagnosis and management of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.